Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Jong-Chan Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6590-2353; OpenAlex author ID A5100686272, A5108822862. Sources: OpenAlex.

Their work

Papers
39 (first author 11, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
47
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: 3 papers · 2020: 7 papers · 2021: 4 papers · 2022: 6 papers · 2023: 2 papers · 2024: 2 papers · 2025: 5 papers · 2026: 4 papers

Papers 39

  1. Comprehensive clinico-genomic analysis of pancreatic ductal adenocarcinoma: Overcoming biases and limitations. First author DOI 10.1016/j.canlet.2025.218176↗
  2. Sensitive fiber-optic localized surface plasmon resonance sensor for early pancreatic cancer detection via carbohydrate antigen 19-9 and supplementary biomarke… Co-author DOI 10.1016/j.talanta.2025.129133↗
  3. Early diagnosis of pancreatic ductal adenocarcinoma by signal-enhanced lateral flow immunoassay: SELFI. Co-author DOI 10.1038/s41467-026-69204-7↗
  4. Chemotherapy for Older Adults with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. Last author DOI 10.3390/jcm15062254↗
  5. Effectiveness and cost analysis of liposomal irinotecan in patients with pancreatic adenocarcinoma: a multicenter real-world study. Co-author DOI 10.1177/17588359251370492↗
  6. Novel mRNA biomarker-based liquid biopsy for the detection of resectable pancreatic cancer. Co-author DOI 10.1186/s12885-025-14124-w↗
  7. Distinct microbiome composition and reduced interactions in patients with pancreatic cancer. Co-author DOI 10.3389/fmicb.2025.1555479↗
  8. Identification of patients with advanced pancreatic cancer who might benefit from third-line chemotherapy. Co-author DOI 10.4251/wjgo.v17.i2.100167↗
  9. Prognostic Value of the Metabolic Response on Serial 18F-FDG PET/CT in Pancreatic Cancer. Co-author DOI 10.5009/gnl240458↗
  10. The Trends and Outcomes of Initial Palliative Chemotherapy in Patients with Pancreatic Cancer in Korea Based on National Health Insurance Service Data. Co-author DOI 10.3390/jcm13113229↗
  11. Analysis of Recent Improvement of Survival Outcomes in Patients with Pancreatic Cancer Who Underwent Upfront Surgery. Co-author DOI 10.5009/gnl230303↗
  12. Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis. Last author DOI 10.1177/17588359231175441↗
  13. Novel mRNA-based Immunological Biomarker for Early Detection of Resectable Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-2658368/v1↗
  14. Tumor resectability and response on CT following neoadjuvant therapy for pancreatic cancer: inter-observer agreement study. Co-author DOI 10.1007/s00330-021-08494-5↗
  15. NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer. Co-author DOI 10.1038/s41598-022-24732-2↗
  16. Association between progression-free survival and metal stent patency in patients with advanced pancreatic cancer. Co-author DOI 10.21037/jgo-22-218↗
  17. Downregulation of ASF1B inhibits tumor progression and enhances efficacy of cisplatin in pancreatic cancer. Co-author DOI 10.3233/cbm-210490↗
  18. Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14102476↗
  19. Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic C… First author DOI 10.5009/gnl20312↗
  20. Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A bi… First author DOI 10.1016/j.pan.2021.02.022↗
  21. Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis. First author DOI 10.1038/s41598-021-99647-5↗
  22. Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients. Co-author DOI 10.1186/s13104-021-05681-x↗
  23. Clinical Impact of Unexpected Para-Aortic Lymph Node Metastasis in Surgery for Resectable Pancreatic Cancer. Last author DOI 10.3390/cancers13174454↗
  24. Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 tria… Co-author DOI 10.1016/j.gie.2020.02.012↗
  25. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2020.06.010↗
  26. Cdc6 disruption leads to centrosome abnormalities and chromosome instability in pancreatic cancer cells. First author DOI 10.1038/s41598-020-73474-6↗
  27. Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry. Co-author DOI 10.1097/coc.0000000000000730↗
  28. Sex Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX Co-author DOI 10.21203/rs.3.rs-33720/v1↗
  29. Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment. Co-author DOI 10.3390/cancers12113137↗
  30. Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator. Co-author DOI 10.5009/gnl19180↗
  31. Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.ejso.2019.06.002↗
  32. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and m… First author DOI 10.1038/s41598-019-52167-9↗
  33. Accuracy of an administrative database for pancreatic cancer by international classification of disease 10th codes: A retrospective large-cohort study. Co-author DOI 10.3748/wjg.v25.i37.5619↗
  34. It is necessary to exam bottom and top slide smears of EUS-FNA for pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2018.08.002↗
  35. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity. Co-author DOI 10.1016/j.ejca.2017.02.010↗
  36. Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer. First author DOI 10.1016/j.surg.2016.12.038↗
  37. Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern. First author DOI 10.1097/md.0000000000005926↗
  38. Characteristics of Venous Thromboembolism in Pancreatic Adenocarcinoma in East Asian Ethnics: A Large Population-Based Observational Study. Co-author DOI 10.1097/md.0000000000003472↗
  39. Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/md.0000000000001012↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin‐Hyeok Hwang · 35 shared papers, 2015–2026 · strength 5.64
  2. Jaihwan Kim · 31 shared papers, 2015–2026 · strength 4.83
  3. Kwangrok Jung · 11 shared papers, 2020–2026 · strength 2.24
  4. Yuna Youn · 8 shared papers, 2020–2026 · strength 1.68
  5. Dong Woo Shin · 8 shared papers, 2019–2026 · strength 1.34
  6. Jinwoo Ahn · 5 shared papers, 2022–2025 · strength 1.12
  7. Yoon Suk Lee · 5 shared papers, 2015–2025 · strength 0.82
  8. Yoo‐Seok Yoon · 6 shared papers, 2017–2024 · strength 0.80
  9. Ho‐Seong Han · 6 shared papers, 2017–2024 · strength 0.80
  10. Jae Hyeong Kim · 4 shared papers, 2020–2026 · strength 0.75
  11. Bo‐Mi Kim · 3 shared papers, 2023–2025 · strength 0.68
  12. Jin Won Kim · 5 shared papers, 2017–2024 · strength 0.66
  13. Young Hoon Kim · 5 shared papers, 2017–2022 · strength 0.65
  14. Sang Myung Woo · 4 shared papers, 2019–2025 · strength 0.65
  15. Jae Hyup Jung · 4 shared papers, 2020–2024 · strength 0.65
  16. Haeryoung Kim · 4 shared papers, 2018–2022 · strength 0.52
  17. Dong Kee Jang · 2 shared papers, 2024–2025 · strength 0.46
  18. Young Ae Kim · 2 shared papers, 2024–2025 · strength 0.46
  19. Jung Won Chun · 2 shared papers, 2024–2025 · strength 0.46
  20. Woo Jin Lee · 3 shared papers, 2019–2025 · strength 0.43
  21. Soomin Ahn · 3 shared papers, 2019–2022 · strength 0.40
  22. Sung‐Hoon Moon · 1 shared paper, 2026 · strength 0.39
  23. Jun Suh Lee · 2 shared papers, 2021–2024 · strength 0.33
  24. Hyeong‐Min Kim · 1 shared paper, 2026 · strength 0.29
  25. Seung-Ki Lee · 1 shared paper, 2026 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.